Drugs / autologous monocyte-derived dendritic cells (DC) transfected with DNA
autologous monocyte-derived dendritic cells (DC) transfected with DNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00377247 | Apr 2009 | head and neck squamous cell carcinoma | University of Pittsburgh | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous monocyte-derived dendritic cells (DC) transfected with DNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00377247 ↗ |
| Modality | Cell therapy | “a new vaccine, consisting of autologous monocyte-derived dendritic cells (DC) transfected with autologous tumor-derived DNA” NCT00377247 ↗ |
| Route | Other | “The patients will receive 1 x 107 DC/vaccine delivered intranodally or perinodally to lymph nodes (LN) distant from the head and neck area” NCT00377247 ↗ |